Stocks

Join David Keller, CMT for a powerful, interactive, and actionable fireside chat on markets in 2026. He will share his analysis of key market trends so far this year – including behind-the-scenes sector rotation, foreign market outperformance, volatility in precious metals, and more. He will also discuss what his technical indicators are showing and how investors and traders can best navigate volatile markets. Plus, he’ll explain what institutional investor-style tactics and strategies you can apply as an individual investor to maximize your portfolio returns.

CounterX Therapeutics is at the forefront of the battle against the opioid epidemic, exploiting cutting-edge biotechnology to develop life-saving therapeutics and vaccines. We combine scientific expertise with an experienced leadership team and a deep commitment to social impact. Our groundbreaking antibody therapies are designed to blunt the effects of opioids, reduce the risk of overdose, and provide a path to recovery. Additionally, our pioneering vaccine technology aims to prevent addiction relapse by blocking the euphoric effects of opioids and empowering individuals to maintain a long-term recovery.

The S&P 500 recorded a “three-peat” in 2025, or three successive years of double-digit gains. What is the likelihood of scoring a “four peat?” Even though CFRA thinks the bull will remain intact by year-end, it projects increased volatility along with a lower-than-average full-year percentage increase. Why so cautious? Still-high valuations, an elevated Buffett Indicator, a softening jobs market, late-cycle and defensive sector leadership, combined with mid-term elections that typically present formidable headwinds. Offsetting tailwinds include the fourth year of this bull market and double-digit earnings growth expectations, not only for 2026 but also for 2027. Sam Stovall, CFRA’s Chief Investment Strategist, will discuss what the market’s recent rotation implies for investor returns in the year ahead.

Small- and mid-cap equities enter 2026 with improving earnings leadership, discounted valuations, and stabilizing business sentiment after several years of lagging performance versus mega-caps. 

Zhittya Genesis Medicine has developed a medicine to treat diseases caused by a lack of blood flow. During this presentation you will explore how Zhittya is using their FGF-1 to treat heart disease, Parkinson's disease, Type-2 Diabetes, and more. 

Kristina Hooper will provide an exploration of the key macroeconomic and market themes shaping the global investment landscape for 2026. Topics will include the potential for a US recession, expectations for monetary and fiscal policy, fiscal sustainability in high-debt-to-GDP countries, and the evolving role of the US as a global safe haven. Will also evaluate the prospects for a European revival, China's resilience, and the implications of geopolitical tensions. Will also discuss market implications.

Small-to-Mid Capitalization stocks are in the midst of an impressive rally.  This is due to third quarter earnings surprises, plus the fact that small-to-mid capitalization stocks are more "domestic" and naturally benefitting from a strong U.S. economy, plus anticipated Fed key interest rate cuts.  When there is an early January effect, then the "real January effect" in the New Year is typically spectacular!  Furthermore, due to all the onshoring efforts, up to 5% annual GDP growth is likely in 2026!  Louis will reveal his favorite small-to-mid capitalization stocks that are poised to prosper.